News and Announcements
Actinogen Medical Provides Quarterly Newsletter Focusing on Brain Awareness Week
- Published March 16, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Actinogen Medical is pleased to provide its latest quarterly newsletter which focuses on Brain Awareness Week (13-19 Mar 2017) – a global campaign to increase public awareness of the progress and benefits of brain research.
KEY TAKEAWAYS:
- One-in-three people will develop Alzheimer’s disease by the time they are 85 and available health budgets cannot cope with managing this disease – it already costs US$250 billion annually in the US alone.
- Dr Bill Ketelbey reflects on his own personal journey to seek a cure for Alzheimer’s disease and the reasons why he joined Actinogen.
- Recent key Australian research may have provided an important clue to how best to develop a new treatment for Alzheimer’s disease and this is why Actinogen Medical’s XanADu program is so keenly watched.
Please Click below for the full Quarterly Investor Newsletter.
Company Updates
The Biofilm Breakthrough: How An Australian BioTech Firm Is Tapping Indonesia’s $45,000-a-Kitchen Bottleneck
Australian sustainability and deep-tech firm Altair International Pty Ltd is commercialising plant-based clinical hygiene technology, targeting a prime operational bottleneck in Indonesia’s massive national free meals program. Every few years, an Australian deep-tech company emerges combining proprietary science with a transformational anchor contract, the kind of business that quietly creates an entirely new market category […]
THE TAX CHANGED. NOW THE PRODUCT IS CHANGING TO MATCH.
Changes to the 50% capital gains tax discount are shifting Australian private capital away from growth and into high-yielding wrappers. Fund managers are actively redesigning products across private credit and property to capture the incoming capital rotation
The Algorithm Re-Dosing Cancer Treatment: Inside the University of Melbourne Spin-Out Rewriting a 60-Year-Old Formula
Oncology specialists are still calculating toxic chemotherapy doses using a formula from the era of the Ford Model T, leading to a system where seven out of eight patients are routinely overdosed. University of Melbourne spin-out PredicTx is dismantling this legacy approach, utilizing advanced AI to analyze existing patient CT scans, deliver precision medicine to the bedside, and return a massive 100x financial rerate to hospital networks.
Backed By Leading Investment Groups and Family Offices
